Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 studyResearch in context
Summary: Background: Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies. In this phase 2 study (CITADEL-205; NCT03235544, EudraCT 2017-003148-19), the efficacy and safety of parsaclisib was eval...
Main Authors: | Pier Luigi Zinzani, Marek Trněný, Vincent Ribrag, Vittorio Ruggero Zilioli, Jan Walewski, Jacob Haaber Christensen, Vincent Delwail, Guillermo Rodriguez, Parameswaran Venugopal, Morton Coleman, Caroline Dartigeas, Caterina Patti, Fabrizio Pane, Wojciech Jurczak, Michal Taszner, Shankara Paneesha, Fred Zheng, Douglas J. DeMarini, Wei Jiang, Aidan Gilmartin, Amitkumar Mehta |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-08-01
|
Series: | EClinicalMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537023003085 |
Similar Items
-
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 studyResearch in context
by: Marek Trněný, et al.
Published: (2023-09-01) -
Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B‐cell malignancies: Results from the CITADEL‐101 study
by: Jia Li, et al.
Published: (2024-04-01) -
Primary dural Lymphoma: A case report
by: IBRAHIM Al-hassana Idriss, et al.
Published: (2024-06-01) -
A Rare Case of Primary Renal Lymphoma: Case report.
by: Smritee Mahat, et al.
Published: (2019-12-01) -
Ocular adnexal lymphoma – a retrospective study and review of the literature
by: Boltezar Lucka, et al.
Published: (2024-09-01)